A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers-Reference-Cited by-同舟云学术

A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhao Nan¹,Jia Bo¹,Zhao Hong²,Xu Junyu¹,Sheng Xiaoyan¹,Luo Lin³,Huang Zhangma³,Wang Xingan³,Ren Qingyun³,Zhang Yingjun³,Zhao Xia¹,Cui Yimin¹

Affiliation:

1. Department of Pharmacy, Peking University First Hospital, Beijing, China

2. Department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, Beijing, China

3. The State Key Laboratory of Anti-Infective Drug Development, HEC R&D Center, Sunshine Lake Pharma Co., Ltd., Dongguan, China

Abstract

GLS4 is a novel inhibitor of the hepatitis B virus (HBV) capsid assembly with inhibitory activities against nucleot(s)ide-resistant HBV strains. This study investigated the pharmacokinetics, safety, and tolerability of GLS4 and the effects of food and ritonavir in healthy adults. GLS4 was administered in a single-ascending-dose study over 1 to 240 mg and multiple-ascending-dose study that ranged from 30 mg once daily to 180 mg three times daily.

Funder

State Key Laboratory of Anti-Infective Drug Development

MOST | National Major Science and Technology Projects of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01686-19

Reference28 articles.

1. Epidemiology of hepatitis B and the role of vaccination

2. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures